Abstract
A randomized controlled study exploring an induction-maintenance strategy was performed with a quadruple-drug regimen: zidovudine/lamivudine/abacavir/nevirapine. The study was prematurely interrupted due to the high proportion of adverse events. The median time on protocol-defined therapy was 110 days; 13/28 (46%) patients interrupted therapy and 2/6 tested patients selected praecox viral mutants. Despite this, we observed a significant (p </= .001) increment of CD4. The theoretical advantages of induction-maintenance strategies are tempered by an increased risk of adverse experiences.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use*
-
Antiretroviral Therapy, Highly Active*
-
CD4 Lymphocyte Count
-
Dideoxynucleosides / administration & dosage
-
Dideoxynucleosides / adverse effects
-
Dideoxynucleosides / therapeutic use
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / pathology
-
Humans
-
Lamivudine / administration & dosage
-
Lamivudine / adverse effects
-
Lamivudine / therapeutic use
-
Male
-
Nevirapine / administration & dosage
-
Nevirapine / adverse effects
-
Nevirapine / therapeutic use
-
Severity of Illness Index
-
Treatment Outcome
-
Zidovudine / administration & dosage
-
Zidovudine / adverse effects
-
Zidovudine / therapeutic use
Substances
-
Anti-HIV Agents
-
Dideoxynucleosides
-
Lamivudine
-
Zidovudine
-
Nevirapine
-
abacavir